151 related articles for article (PubMed ID: 24900493)
1. Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.
Cho YS; Angove H; Brain C; Chen CH; Cheng H; Cheng R; Chopra R; Chung K; Congreve M; Dagostin C; Davis DJ; Feltell R; Giraldes J; Hiscock SD; Kim S; Kovats S; Lagu B; Lewry K; Loo A; Lu Y; Luzzio M; Maniara W; McMenamin R; Mortenson PN; Benning R; O'Reilly M; Rees DC; Shen J; Smith T; Wang Y; Williams G; Woolford AJ; Wrona W; Xu M; Yang F; Howard S
ACS Med Chem Lett; 2012 Jun; 3(6):445-9. PubMed ID: 24900493
[TBL] [Abstract][Full Text] [Related]
2. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
3. Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo.
Hirai H; Shimomura T; Kobayashi M; Eguchi T; Taniguchi E; Fukasawa K; Machida T; Oki H; Arai T; Ichikawa K; Hasako S; Haze K; Kodera T; Kawanishi N; Takahashi-Suziki I; Nakatsuru Y; Kotani H; Iwasawa Y
Cell Cycle; 2010 Apr; 9(8):1590-600. PubMed ID: 20372067
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements.
Liu S; Bolger JK; Kirkland LO; Premnath PN; McInnes C
ACS Chem Biol; 2010 Dec; 5(12):1169-82. PubMed ID: 20843055
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy.
Zha C; Deng W; Fu Y; Tang S; Lan X; Ye Y; Su Y; Jiang L; Chen Y; Huang Y; Ding J; Geng M; Huang M; Wan H
Eur J Med Chem; 2018 Mar; 148():140-153. PubMed ID: 29459274
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle.
Zanuy M; Ramos-Montoya A; Villacañas O; Canela N; Miranda A; Aguilar E; Agell N; Bachs O; Rubio-Martinez J; Pujol MD; Lee WN; Marin S; Cascante M
Metabolomics; 2012 Jun; 8(3):454-464. PubMed ID: 22661920
[TBL] [Abstract][Full Text] [Related]
7. Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.
Tadesse S; Bantie L; Tomusange K; Yu M; Islam S; Bykovska N; Noll B; Zhu G; Li P; Lam F; Kumarasiri M; Milne R; Wang S
Br J Pharmacol; 2018 Jun; 175(12):2399-2413. PubMed ID: 28800675
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.
Fry DW; Bedford DC; Harvey PH; Fritsch A; Keller PR; Wu Z; Dobrusin E; Leopold WR; Fattaey A; Garrett MD
J Biol Chem; 2001 May; 276(20):16617-23. PubMed ID: 11278443
[TBL] [Abstract][Full Text] [Related]
9. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening.
Yuan K; Min W; Wang X; Li J; Kuang W; Zhang F; Xie S; Yang P
Future Med Chem; 2020 Jun; 12(12):1121-1136. PubMed ID: 32400188
[No Abstract] [Full Text] [Related]
11. Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors.
Grimster NP; Anderson E; Alimzhanov M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Gero T; Harsch A; Huszar D; Kawatkar A; Kettle JG; Lyne P; Read JA; Rivard Costa C; Ruston L; Schroeder P; Shi J; Su Q; Throner S; Toader D; Vasbinder M; Woessner R; Wang H; Wu A; Ye M; Zheng W; Zinda M
J Med Chem; 2018 Jun; 61(12):5235-5244. PubMed ID: 29856615
[TBL] [Abstract][Full Text] [Related]
12. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
[TBL] [Abstract][Full Text] [Related]
13. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.
Yang C; Li Z; Bhatt T; Dickler M; Giri D; Scaltriti M; Baselga J; Rosen N; Chandarlapaty S
Oncogene; 2017 Apr; 36(16):2255-2264. PubMed ID: 27748766
[TBL] [Abstract][Full Text] [Related]
14. The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.
Ren L; Ahrendt KA; Grina J; Laird ER; Buckmelter AJ; Hansen JD; Newhouse B; Moreno D; Wenglowsky S; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Risom T; Sturgis HL; Voegtli WC; Mathieu S
Bioorg Med Chem Lett; 2012 May; 22(10):3387-91. PubMed ID: 22534450
[TBL] [Abstract][Full Text] [Related]
15. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.
Cho YS; Borland M; Brain C; Chen CH; Cheng H; Chopra R; Chung K; Groarke J; He G; Hou Y; Kim S; Kovats S; Lu Y; O'Reilly M; Shen J; Smith T; Trakshel G; Vögtle M; Xu M; Xu M; Sung MJ
J Med Chem; 2010 Nov; 53(22):7938-57. PubMed ID: 21038853
[TBL] [Abstract][Full Text] [Related]
16. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.
Chiron D; Martin P; Di Liberto M; Huang X; Ely S; Lannutti BJ; Leonard JP; Mason CE; Chen-Kiang S
Cell Cycle; 2013 Jun; 12(12):1892-900. PubMed ID: 23676220
[TBL] [Abstract][Full Text] [Related]
17. Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.
Tadesse S; Yu M; Mekonnen LB; Lam F; Islam S; Tomusange K; Rahaman MH; Noll B; Basnet SK; Teo T; Albrecht H; Milne R; Wang S
J Med Chem; 2017 Mar; 60(5):1892-1915. PubMed ID: 28156111
[TBL] [Abstract][Full Text] [Related]
18. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.
Guan KL; Jenkins CW; Li Y; Nichols MA; Wu X; O'Keefe CL; Matera AG; Xiong Y
Genes Dev; 1994 Dec; 8(24):2939-52. PubMed ID: 8001816
[TBL] [Abstract][Full Text] [Related]
19. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
Said TK; Medina D
Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
[TBL] [Abstract][Full Text] [Related]
20. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
